Vivos

RDGL

Medical - Devices · Healthcare

Price

$0.06

+0.00 (+0.34%)

Market Cap

$29.6M

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Share count rising — dilution

+38.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 325.9M (2021) → 452.7M (2025)

Vivos Inc. is a small medical device company that makes a radioactive liquid used to treat cancer tumors. Its main product is called Rhenium-188 NanoLiposome (186RNL), which is injected directly into brain tumors to kill cancer cells from the inside. The company is focused on a type of brain cancer called glioblastoma, one of the deadliest and hardest-to-treat cancers.

Vivos earns revenue by developing and eventually selling its radioactive drug therapy, though it is still in early clinical trials and has not yet generated meaningful commercial sales. It operates primarily in the United States and is an extremely small company with a market cap near zero. The deeply negative margins reflect a business that is spending heavily on research while earning almost nothing — the central risk is that it may run out of cash before proving its treatment works well enough to win regulatory approval.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+34.8% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

-36.8% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$352,232/ year

↑ Rising (+9% vs prior year)

515.1% of revenue

28.6x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

3.9%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~13 months

$3M cash & investments

Quarterly Free Cash Flow

Adequate runway but may need to raise capital within 2 years

Strong grower

Vivos is growing revenue at 35% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

0.0%

Thin — 0.0% gross margin

Operating Margin

-1772.6%

Losing money on operations — -1772.6%

ROCE

-22.8%

Weak — -22.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+54.6%

Fast-growing sales (54.6% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-2943.1%

Burning cash (-2943.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.04

Conservative — low debt load (0.04)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial